Manuel Nicolás
Hernández Guerra de Aguilar
Profesor Titular Universidad
Hospital Universitario 12 de Octubre
Madrid, EspañaHospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (11)
2024
-
Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice
Alimentary Pharmacology and Therapeutics
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics
2023
-
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Hepatology, Vol. 77, Núm. 4, pp. 1095-1105
2022
-
Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes
Gut, Vol. 71, Núm. 10, pp. 2138-2140
2021
-
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
-
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592
-
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
PLoS ONE, Vol. 14, Núm. 11
2016
-
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
Journal of Hepatology, Vol. 65, Núm. 3, pp. 532-542
2015
-
High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain
Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486